Catalog # G4S-PFMY25



#### Source

Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016) is a rabbit monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.

### Application

Flow Cytometry (Evaluation of cell surface expressed CARs of varying specificity containing a G4S linker within the scFv of the extracellular domain).

### Clone

016

Species

Rabbit

# Isotype

Rabbit IgG | Rabbit Kappa

# Specificity

Specifically recognizes the scFv-based CARs containing a G4S linker.


## Conjugate

### PE

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

## **Bioactivity-FACS**



### **Recommended Dilution**

1:50

### Formulation

Lyophilized from 0.22  $\mu$ m filtered solution in PBS, 0.03% Proclin 300, pH7.4, 0.2% BSA with trehalose as protectant.

Contact us for customized product form or formulation.

### Reconstitution

Please see Certificate of Analysis for specific instructions.


For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

### Storage

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months after reconstitution.




Flow cytometric analysis of Anti-MSLN CAR-293 cells staining with PE-Labeled Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016) (Cat. No. G4S-PFMY25) at 1:50 dilution (2  $\mu$ L of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100  $\mu$ L), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested). Non-specificity of PE-Labeled Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016) (Cat. No. G4S-PFMY25) binding to CD3+ cells present in human PBMC. 5e5 of human PBMCs were simultaneously stained with FITC-labeled anti-CD3 antibody and PE-Labeled Monoclonal Anti-G4S linker Antibody (2  $\mu$ L of the antibody stock solution corresponds to labeling of 5e5 cells in a final volume of 100  $\mu$ L) and washed and then analyzed with FACS. Both FITC and











Flow cytometric analysis of Anti-CD19 CAR-293 cells staining with PE-Labeled Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016) (Cat. No. G4S-PFMY25) at 1:50 dilution (2  $\mu$ L of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100  $\mu$ L), compared with isotype control antibody. PE signal was used to evaluate the binding activity (Routinely tested).


### **Compared Data**



BIOSYSTEMS



Flow cytometric analysis of Anti-CD22 CAR-293 cells staining with PE-Labeled Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016) (Cat. No. G4S-PFMY25) at 1:50 dilution (2  $\mu$ L of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100  $\mu$ L), compared with isotype control antibody. PE signal was used to evaluate the binding activity (Routinely tested).



Flow cytometric analysis of Anti-CD19 CAR-293 cells staining with PE-Labeled Monoclonal Anti-G4S linker Antibodies. PE signal was used to evaluate the binding activity of anti-G4S linker antibody. The biological activity level of Acro is superior to competitor C (Routinely tested).

### Background

The poly-Glycine-Serine (G4S) linker is a type of flexible, unstructured synthetic peptide linker sequence often leveraged to connect the variable heavy (VH) domain and variable light (VL) domain of single-chain variable fragments (scFvs) and chimeric antigen receptors (CARs) that utilize an extracellular domain scFv for target

antigen recognition. The linker itself consists of a core pentapeptide sequence, Gly-Gly-Gly-Gly-Ser, that is repeated and commonly found as either a 15-mer (G4S)3 or20-mer(G4S) 4 within scFv-based CARs and scFv fragments. The linker sequence length plays a role in controlling scFv stability and the noncovalent association between the VH and VL domains.

**Clinical and Translational Updates** 



